LFMD — LifeMD, Inc.

LifeMD (LFMD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Consolidated revenue grew 13% year-over-year to $60.2 million.
• Telehealth Revenue: Increased 18% to $47.3 million.
• Adjusted EBITDA: Rose 30% to $5.1 million; telehealth adjusted EBITDA was $2.9 million.
• Net Loss: GAAP net loss attributable to common stockholders was $4.6 million ($0.10 per share), an improvement from a loss of $5.4 million ($0.13 per share) in Q3 2024.
• Subscriber Growth: Active telehealth subscribers increased 14% year-over-year to over 310,000.
• Gross Margin: Consolidated gross margin was 88%, down 290 basis points from the previous year due to revenue mix.

2. Strategic Updates and Business Highlights

• RexMD Growth: The RexMD business added approximately 10,000 net new subscribers, rebounding from previous lows.
• Weight Management Offering: Stabilized and positioned for growth in 2026, with a focus on collaborations with Novo Nordisk and Eli Lilly.
• New Offerings: Significant progress in women's health and behavioral health services, with expectations for these to become substantial revenue streams.
• Compounding Pharmacy: Secured regulatory approval for a nonsterile 503-A compounding pharmacy, enhancing the ability to produce personalized medications and improve margins.
• Divestiture: Successfully divested majority interest in WorkSimpli to focus on core telehealth and pharmacy operations.

3. Forward Guidance and Outlook

• Q4 2025 Revenue Guidance: Expected in the range of $45 million to $46 million; adjusted EBITDA projected between $3 million and $4 million.
• Full Year 2025 Guidance: Revenue anticipated between $192 million and $193 million, representing 24% growth; adjusted EBITDA expected between $13.5 million and $14.5 million, a 254% increase compared to 2024.
• 2026 Focus: Plans to accelerate growth in weight management, expand women's and behavioral health services, and enhance the LifeMD platform and marketplace.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Intense competition in the weight management category from low-cost compounded GLP-1 therapies, making it difficult to compete on price.
• Gross Margin Decline: Telehealth gross margin decreased due to a shift towards branded products, which carry lower fulfillment fees compared to personalized compounds.
• Insurance Enablement Delays: Although insurance coverage is being implemented, the rollout has been slower than anticipated, which could impact patient acquisition and revenue growth.

5. Notable Q&A Insights

• Revenue Mix: Weight management remains over 50% of total revenue, with more than half of new patient sign-ups coming from branded therapies.
• Insurance Impact: A significant percentage of patients (around 25%) drop out due to lack of insurance coverage; enabling insurance is expected to enhance patient retention and acquisition.
• Market Potential for Oral Therapies: Anticipated launch of the Wegovy pill could expand the market significantly, with estimates suggesting a potential 25% to 50% increase in uptake due to preference for oral medications.
• Retention and Differentiation: LifeMD's comprehensive service offerings and provider access are seen as key differentiators compared to competitors like Costco or Amazon, which lack integrated healthcare services.

Overall, LifeMD demonstrated solid financial growth in Q3 2025, with strategic initiatives aimed at enhancing its service offerings and market position, despite facing competitive challenges and margin pressures. The company remains optimistic about future growth, particularly with upcoming product launches and insurance coverage expansions.